The Evolving Role of FLT3 Inhibitors in Acute Myeloid Leukemia: Quizartinib and Beyond

Therapeutic Advances in Hematology - United States
doi 10.1177/2040620714532123
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

SAGE Publications

Related search

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best When the Optimal Does Not Exist

American Journal of Hematology
Hematology
2018English

FLT3-TKD Mutation in Childhood Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2003English

Profile of Quizartinib for the Treatment of Adult Patients With Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date

Cancer Management and Research
Oncology
2020English

CDK9 Inhibitors in Acute Myeloid Leukemia

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

8-Chloro-Adenosine Activity in FLT3-ITD Acute Myeloid Leukemia

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2019English

DNA Damage on the DOCK in FLT3-ITD-driven Acute Myeloid Leukemia

Haematologica
Hematology
2019English

Targeting BTK for the Treatment of FLT3-ITD Mutated Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2015English

mTOR Signaling Is Activated by FLT3 Kinase and Promotes Survival of FLT3-mutated Acute Myeloid Leukemia Cells

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy